Article Information
History
- February 21, 2022.
Article Versions
- Version 1 (November 9, 2021 - 09:21).
- Version 2 (February 10, 2022 - 06:54).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Robert E Dewhurst1,2,
- Tatjana Heinrich1,2,
- Paul Watt2,3,
- Paul Ostergaard2,
- Jose Maria Marimon4,
- Mariana Moreira5,
- Philip E Houldsworth5,
- Jack D Rudrum1,2,
- David Wood6 and
- Sulev Kõks1,7,8,*
- 1Perron Institute for Neurological and Translational Science; Perth, 6009, Western Australia, Australia
- 2Avicena Systems Ltd, West Perth, 6005, Western Australia
- 3Telethon Kids Institute, University of Western Australia, Perth, 6009, Western Australia
- 4Biodonostia Health Research Institute, Infectious Diseases Area, Osakidetza Basque Health Service, Donostialdea Integrated Health Organization, San Sebastián, Spain
- 5Lancs Lamp Laboratory, Heatley House, Bowran Street, Preston, PR1 2UX, United Kingdom
- 6University of Western Australia; Perth, 6009, Western Australia
- 7Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, 6150, Western Australia
- 8Prion Ltd, Tartu, 50410, Estonia
- ↵*Corresponding author. Email: sulev.koks{at}perron.uwa.edu.au